Anthem Inc


Latest Trade






Today's Range




52 Week Range




As of on the New York Stock Exchange ∙ Minimum 15 minute delay


Previous Close
3M AVG Volume
Today's High
Today's Low
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Forward P/E
Dividend (Yield %)

Next Event

Q3 2019 Anthem Inc Earnings Release

Latest Developments


Centene And Wellcare Announce Agreement Between Wellcare And Anthem To Divest Missouri And Nebraska Medicaid Plans

Anthem Intends To Reaffirm Net Income Guidance For FY 2019 To Be More Than $18.34 Per Share, Including About $0.96 Per Share Of Net Unfavorable Items

Anthem Inc Prices Three-Part Notes Offering Of Up To $2.5 Bln


About Anthem Inc

Anthem, Inc. is a health benefits company. The Company operates through three segments: Commercial and Specialty Business, Government Business and Other. It offers a spectrum of network-based managed care plans to large and small employer, individual, Medicaid and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. It also provides an array of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs and other administrative services. It provides an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits and radiology benefit management.


Insurance (Accident & Health)

Contact Info

220 Virginia Avenue


Executive Leadership

Elizabeth E. Tallett

Independent Chairman of the Board

Gail Koziara Boudreaux

President, Chief Executive Officer, Director

Felicia F. Norwood

EVP and President, Government Business Division

John E. Gallina

Chief Financial Officer, Executive Vice President

Prakash R. Patel

Executive Vice President and President, Diversified Business Group

Key Stats

1.75 mean rating - 24 analysts
Revenue (MM, USD)
















Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)

Latest News

Latest News

Centene, WellCare to divest certain Medicaid plans to Anthem

Centene Corp <CNC.N> and Wellcare Health Plans Inc <WCG.N> have agreed to sell Wellcare's Missouri and Nebraska Medicaid plans for people with low income to Anthem Inc <ANTM.N>, as the companies look to close their $15.27 billion deal.

Anthem shares sink as cost concerns overshadow earnings beat

Anthem Inc <ANTM.N> shares fell as much as 4% on Wednesday after the U.S. health insurer missed Wall Street expectations for a key medical cost gauge as a result of higher costs of selling Medicaid health plans for low-income customers.

Anthem Inc reports 8% rise in quarterly profit

Anthem Inc reported an 8% rise in second-quarter profit on Wednesday as the U.S. health insurer benefited from higher sales of its government-backed health plans.

Anthem beats earnings estimates, outlines plans for pharmacy benefits unit

Anthem Inc on Wednesday posted a better-than-expected quarterly profit and laid out its plans to transition most customers to its revamped pharmacy benefits business this year.

Anthem posts 18.2 percent rise in first-quarter profit

Health insurer Anthem Inc reported an 18.2 percent rise in quarterly profit on Wednesday, as revenue from its commercial and government businesses rose.

House panel probes Anthem, UnitedHealth over short-term health plans

The U.S. House Committee on Energy and Commerce on Wednesday launched an investigation into 12 health insurers, including Anthem Inc and UnitedHealth Group, over their sale of short-term plans.

Anthem speeds up pharmacy benefits launch, shares jump 10 percent

Anthem Inc <ANTM.N> surprised Wall Street on Wednesday by moving up the launch of its in-house pharmacy benefits management business, sending shares 10 percent higher as investors welcomed the decision after rival health insurers signed multibillion-dollar deals joining...

Health insurer Anthem's fourth-quarter revenue rises 3 pct

Anthem Inc reported a 3 percent rise in quarterly revenue on Wednesday as the health insurer benefited from premium rate increases.

Anthem predicts better 2019 than Wall Street forecast, shares rise

Anthem Inc <ANTM.N> on Wednesday said its own expectations for 2019 earnings are ahead of current Wall Street estimates and the health insurer also raised its 2018 profit forecast, and its shares rose as much as 5 percent.

CORRECTED-UPDATE 1-Anthem quarterly profit beats estimates, raises 2018 forecast

Anthem Inc reported quarterly profit that topped analysts' estimates on Wednesday on lower medical costs and the No.2 U.S. health insurer raised its full-year adjusted earnings forecast.

Takeda hikes annual profit forecast by a third after second-quarter profit jump

Japan's Takeda Pharmaceutical Co Ltd <4502.T> on Wednesday boosted its annual operating profit outlook by a third after second-quarter earnings surged on strong global sales of its drugs for bowel disease and multiple myeloma.

Anthem reports 28.5 pct rise in quarterly profit

Anthem Inc reported a 28.5 percent rise in quarterly profit on Wednesday, as the U.S. health insurer reined in medical costs.

Takeda's raises full-year outlook after Q2 profit rise

Takeda Pharmaceutical Co Ltd on Wednesday raised its annual operating profit outlook to 268.9 billion yen.

Takeda proposes sale of Shire drug to gain European approval

Takeda Pharmaceutical Co Ltd <4502.T> has proposed to European regulators it could sell a Shire <SHP.L> treatment in development due to concerns of overlap in inflammatory bowel disease treatments and its own drug Entyvio as it seeks clearance for the two companies' merger.

Takeda gets Japanese approval for $62 billion Shire purchase

Takeda Pharmaceutical Co Ltd <4502.T> said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc <SHP.L>, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Takeda gets Japan's approval for $62 bln Shire purchase

Takeda Pharmaceutical Co Ltd said on Thursday Japan's Fair Trade Commission had approved its $62 billion acquisition of Shire Plc, bringing the Japanese firm closer to sealing a deal that will make it a global top 10 drugmaker.

Louisiana wins revival of lawsuit against Takeda over Actos cancer risks

A Louisiana appellate court has revived a lawsuit by the state's attorney general accusing Takeda Pharmaceutical Co Ltd of engaging in a fraudulent campaign to mislead the state about the risks of cancer associated with its diabetes drug Actos.

Anthem ties-up with Walmart for over-the-counter drugs

Anthem Inc <ANTM.N> said on Monday it has partnered with Walmart Inc <WMT.N> to launch a program in January 2019 that will allow its Medicare Advantage plan customers to purchase over-the-counter medications from the retailer's stores and website.

Insurer Anthem profit beats estimates on lower patient costs

Anthem Inc <ANTM.N> reported a better-than-expected profit on Wednesday, driven by higher premiums and lower patient medical costs even as fewer people enrolled in its insurance plans.

U.S. health insurer Anthem quarterly profit rises 23 pct

Anthem Inc reported a 23 percent rise in quarterly profit on Wednesday, helped by premium rate increases.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.